Citation Impact
Citing Papers
2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines
2016 Standout
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
2012 Standout
Rational Combinations of Trastuzumab With Chemotherapeutic Drugs Used in the Treatment of Breast Cancer
2004
A Combination of Chemoimmunotherapies Can Efficiently Break Self-Tolerance and Induce Antitumor Immunity in a Tolerogenic Murine Tumor Model
2007 StandoutNobel
Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
1999 Standout
ERBB receptors and cancer: the complexity of targeted inhibitors
2005 Standout
Concurrent Cisplatin-Based Radiotherapy and Chemotherapy for Locally Advanced Cervical Cancer
1999 Standout
The re-emergence of natural products for drug discovery in the genomics era
2015 Standout
Etoposide: four decades of development of a topoisomerase II inhibitor
1998 Standout
Gonadotropin-releasing hormone analogs and prostatic cancer
1988
Doxorubicin-induced cardiomyopathy: From molecular mechanisms to therapeutic strategies
2012 Standout
Cisplatin, Radiation, and Adjuvant Hysterectomy Compared with Radiation and Adjuvant Hysterectomy for Bulky Stage IB Cervical Carcinoma
1999 Standout
Apoptosis. Its significance in cancer and cancer Therapy
1994 Standout
Doxorubicin pathways
2010 Standout
Estimating kinetic parameters from dynamic contrast-enhanced t1-weighted MRI of a diffusable tracer: Standardized quantities and symbols
1999 Standout
Perspectives on cancer therapy-induced mucosal injury
2004 Standout
Inflammatory breast cancer: a review.
1992
Mitoxantrone
1991
Role of Gemcitabine in Breast Cancer Management: An Update
2006
Double-blind randomised trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide
1991
Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer
1999 Standout
Survey of the use of the ICRU 38 in recording and reporting cervical cancer brachytherapy
2001
Drug development from marine natural products
2008 Standout
Fitting of normal tissue tolerance data to an analytic function
1991 Standout
Biologic Rhythms in the Immune System
1999
Paclitaxel (Taxol)
1995 Standout
Docetaxel in combination with doxorubicin or vinorelbine
1997
Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity
2004 Standout
The role of the liposomal anthracyclines and other systemic therapies in the management of advanced breast cancer
2004
Relative biological effectiveness (RBE) values for proton beam therapy
2002 Standout
Different anthracycline derivates for reducing cardiotoxicity in cancer patients
2010
Anthrazykline in der Krebstherapie
1997 Standout
Morbidity and survival patterns in patients after radical hysterectomy and postoperative adjuvant pelvic radiotherapy
1990
FIGO IIIB squamous cell carcinoma of the cervix: an analysis of prognostic factors emphasizing the balance between external beam and intracavitary radiation therapy
1999
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Chemotherapy-Induced Anemia in Adults: Incidence and Treatment
1999
Inhibitors of VIM-2 by screening pharmacologically active and click-chemistry compound libraries
2009 StandoutNobel
Potential Role of Oral Anthracyclines in Older Patients with Cancer
1994
Trastuzumab — Mechanism of Action and Use in Clinical Practice
2007 Standout
Tolerance of normal tissue to therapeutic irradiation
1991 Standout
Circadian control of the immune system
2013 Standout
Phase II study of vinorelbine administered by 96-hour infusion in patients with advanced breast carcinoma
1999
Randomized comparison of vinorelbine and melphalan in anthracycline-refractory advanced breast cancer.
1995
2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours
2010 Standout
Anti-tumor activity of capecitabine and vinorelbine in patients with anthracycline- and taxane-pretreated metastatic breast cancer: Findings from the EORTC 10001 randomized phase II trial
2007
Chemotherapy-Induced Nausea and Vomiting
2008 Standout
Bladder and rectum dose defined from MRI based treatment planning for cervix cancer brachytherapy: comparison of dose–volume histograms for organ contours and organ wall, comparison with ICRU rectum and bladder reference point
2003
Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer.
1995
Cancer and Radiation Therapy: Current Advances and Future Directions
2012 Standout
Microtubule-binding agents: a dynamic field of cancer therapeutics
2010 Standout
Comparison of radiography- and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects
2001
Microtubules as a target for anticancer drugs
2004 Standout
The manufacturing techniques of various drug loaded biodegradable poly(lactide-co-glycolide) (PLGA) devices
2000 Standout
Recommendations from gynaecological (GYN) GEC ESTRO working group (II): Concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy—3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology
2006 Standout
Active cell death in hormone-dependent tissues
1992
Ixabepilone for the treatment of breast cancer
2011
Lymphedema beyond breast cancer
2010 Standout
Idarubicin
1991
The response of the urinary bladder, urethra, and ureter to radiation and chemotherapy
1995
Extended Field Radiation and Cisplatin for Stage IIB and IIIB Cervical Carcinoma
1997
Vinorelbine (Navelbine) as a salvage treatment for advanced breast cancer
1994
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Phase II Trial of Vinorelbine in Recurrent and Progressive Epithelial Ovarian Cancer
1999
Phase II Trial of Dolastatin‐10, a Novel Anti‐Tubulin Agent, in Metastatic Soft Tissue Sarcomas
2004
Tumor perfusion studies using fast magnetic resonance imaging technique in advanced cervical cancer: A new noninvasive predictive assay
1996
Cervical cancer
2019 Standout
Anemia of Chronic Disease
2005 Standout
Pretreatment and treatment factors associated with improved outcome in squamous cell carcinoma of the uterine cervix: A final report of the 1973 and 1978 patterns of care studies
1991
The history and future of targeting cyclin-dependent kinases in cancer therapy
2015 Standout
Phase I Study of Vinorelbine and Docetaxel with Granulocyte Colony-Stimulating Factor Support in the Treatment of Metastatic Breast Cancer
2002
Cancer of the Ovary
2004 Standout
Tumour stem cells and drug resistance
2005 Standout
Neuropathy associated with microtubule inhibitors: diagnosis, incidence, and management.
2008
Oral Idarubicin in Solid Tumour Chemotherapy
1995
Monotherapy options in the management of metastatic breast cancer
2003
Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
1985 Nobel
ICRP PUBLICATION 118: ICRP Statement on Tissue Reactions and Early and Late Effects of Radiation in Normal Tissues and Organs — Threshold Doses for Tissue Reactions in a Radiation Protection Context
2012 Standout
Degradable Controlled-Release Polymers and Polymeric Nanoparticles: Mechanisms of Controlling Drug Release
2016 Standout
Phase II Trial of Weekly Vinorelbine and Trastuzumab as First-Line Therapy in Patients with HER2+ Metastatic Breast Cancer
2002
Radiosurgery for malignant meningioma: results in 22 patients
2000 StandoutNobel
Phase II Study of Eribulin Mesylate, a Halichondrin B Analog, in Patients With Metastatic Breast Cancer Previously Treated With an Anthracycline and a Taxane
2009
Phase III Comparative Study of Vinorelbine Combined With Doxorubicin Versus Doxorubicin Alone in Disseminated Metastatic/Recurrent Breast Cancer: National Cancer Institute of Canada Clinical Trials Group Study MA8
2000
Factors Predicting for Efficacy and Safety of Docetaxel in a Compassionate-Use Cohort of 825 Heavily Pretreated Advanced Breast Cancer Patients
2000
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
1997 Standout
Controls of Hair Follicle Cycling
2001 Standout
New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?
2006 Standout
Mitoxantrone: A New Anticancer Drug with Significant Clinical Activity
1986
Safety and efficacy of the multidrug-resistance inhibitor biricodar (VX-710) with concurrent doxorubicin in patients with anthracycline-resistant advanced soft tissue sarcoma.
2002
Flavopiridol in Untreated or Relapsed Mantle-Cell Lymphoma: Results of a Phase II Study of the National Cancer Institute of Canada Clinical Trials Group
2003
Phase I/II Study Of Concomitant Irradiation and Carboplatin for Locally Advanced Carcinoma of the Uterine Cervix: An Interim Report
1996
Anthraquinones As Pharmacological Tools and Drugs
2016 Standout
Dose-finding and pharmacologic study of chronic oral idarubicin therapy in metastatic breast cancer patients.
2000
Damage to DNA by reactive oxygen and nitrogen species: role in inflammatory disease and progression to cancer
1996 Standout
Works of R Keiling being referenced
Phase II trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy.
1993
Phase II trial of idarubicin (4-demethoxydaunorubicin) in advanced breast cancer
1989
Phase II Trials of Tetrahydropyranyl-Adriamycin (Pirarubicin) on Renal and Colon Carcinoma, Melanoma, and Soft Tissue Sarcoma
1993
Radiotherapy alone in carcinoma of the intact uterine cervix according to G. H. Fletcher guidelines: A french cooperative study of 1383 cases
1988
Variations in the percentages of lymphocyte subtypes during the menstrual cycle in women.
1988
Die französische FAC-vs-FEC-Studie bei fortgeschrittenen Mammakarzinomen
1986
An EORTC phase II study of mitoxantrone in solid tumors and lymphomas
1984
An oriented phase-II trial ofd-Trp6-LH-RH in patients with prostatic carcinoma
1984 Nobel
Preoperative chemotherapy in the treatment of inflammatory breast cancer.
1985
Results of radiotherapy alone in 581 patients with stage II carcinoma of the uterine cervix
1985
Mitoxantrone combined to vincristine, cyclophosphamide and fluorouracil in advanced breast cancer
1985
Mitoxantrone combined with vincristine, cyclophosphamide and fluorouracil for advanced breast cancer. A study of short-term response rate.
1987
A quantified approach to the analysis and prevention of urinary complications in radiotherapeutic treatment of cancer of the cervix
1987
Phase II trial with D‐Trp‐6‐LH‐RH in prostatic carcinoma: Comparison with other hormonal agents
1986 Nobel